Marianne De Backer is President, Chief Executive Officer and Director of Vir Biotechnology, Inc. (VIR). The company reported total compensation of $7,834,045 for fiscal year 2025.
| Salary | $950,000 |
|---|---|
| Bonus | $0 |
| Stock awards | $2,296,800 |
| Option awards | $3,507,360 |
| Non-equity incentive plan | $1,002,750 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $77,135 |
| Total | $7,834,045 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Vir Biotechnology, Inc. filed April 16, 2026, accession 0001628280-26-025379.
| Peer-group chief executive median | $12,231,841 |
|---|---|
| Difference from that median | $-4,397,796 |
| Percentile within the disclosed peer group | 25th |
| Peers with a disclosed figure | 4 |
Medians and percentiles are computed across the peer group Vir Biotechnology, Inc. discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Marianne De Backer this page | President, Chief Executive Officer and Director | $7,834,045 |
| Mark Eisner | Executive Vice President and Chief Medical Officer | $2,371,484 |
| Jason O'Byrne | Executive Vice President and Chief Financial Officer | $1,951,828 |
| Vanina de Verneuil | Executive Vice President, General Counsel and Corporate Secretary | $1,690,784 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Vir Biotechnology, Inc. compensation brief.
Marianne De Backer's compensation sits inside Vir Biotechnology, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.